153 results on '"Komaki, R."'
Search Results
2. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non–small-cell lung cancer treated with induction chemotherapy followed by surgery
3. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04
4. Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: analysis of the radiation therapy oncology group experience
5. P1.20 Metabolic Responses to Metformin in Early-Stage NSCLC Treated with Definitive Radiotherapy: Results of a Phase II Trial
6. MA 13.08 Long Term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a Randomized Phase II Study of 2 SBRT Schedules for Lung Cancer
7. MA 01.10 Outcome Based on Baseline Total Lymphocyte Count & Neutrophil-To-Lymphocyte Ratio in Extensive Stage Small-Cell Lung Cancer
8. OA 08.05 Major Drivers of Chemotherapy and Radiation Utilization for Limited-Stage Small Cell Lung Cancer in the United States
9. PC 02.01 Thoracic Radiation - YES
10. The 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy: Locally Advanced Non-Small Cell Lung Cancer
11. Serum CRP Is Predictive if Survival in Non-Small-Cell Lung Cancer Patients Treated With Definitive Chemoradiation Therapy
12. MEK Inhibition by Selumetinib Enhances the Antitumor and Anti-Metastatic Effects of Chemoradiation Therapy in Orthotopic Human Lung Cancer Models
13. Preclinical Studies of Metformin Reveal Radiosensitization for Human Small Cell Lung Cancer In Vitro But Apparent Antagonism In Vivo
14. The 5-Year Outcome for Patients Diagnosed With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Concurrent Chemotherapy and Proton Beam Therapy
15. Predictors of Site-Specific Distant Metastasis After Definitive Radiation Therapy in Non-Small Cell Lung Cancer and the Impact of Metastatic Location on Survival
16. Lymphopenia Association With Low Lung Dose and its Effects on Non-Small Cell Lung Cancer Patient Outcomes
17. Improving the Quality of Radiation Oncology Education Through an Innovative Medical Student Treatment Planning Curriculum
18. Conformal Fields in Postoperative Radiation Therapy for NSCLC Are Not Associated With High Rates of Regional Nodal Recurrence
19. Serum VEGF Associated With Survival in Non-Small Cell Lung Cancer Patients Treated With Definitive Chemoradiation Therapy
20. High Throughput Clonogenic Survival Screen Identifies Novel Radiation Sensitizers for K-ras Mutant Non-Small Cell Lung Cancer
21. Cardiac Isodose Distributions and Increases in Focal 18F-Fluorodeoxyglucose Uptake on Positron Emission Tomography After Thoracic Stereotactic Ablative Radiation Therapy
22. Dosimetric Impact of Induction Chemotherapy on Subsequent Radiation Treatment Planning in Patients With Inoperable Non-Small Cell Lung Cancer
23. Improved 5-Year Disease Free-Survival and Distant Metastasis-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer Who Had 18F-fluorodeoxyglucose Positron Emission Tomography (PET) or PET/CT Before Chemoradiation Therapy
24. High Local Failure Rates Despite Dose Escalation May Support the Metastatic Self-Seeding Phenomenon in Non-Small Cell Lung Cancer
25. Clinical Outcome and Toxicity in Central Located Stage I or Isolated Recurrent Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy
26. Toxicity and Local Control With Intensity Modulated Radiation Therapy (IMRT) Using a Simultaneous Integrated Boost (SIB) Hypofractionated Approach for Non-Small Cell Lung Cancer (NSCLC)
27. Dosimetric Predictors for Nausea and Anorexia in Esophageal Cancer Patients Treated With Neoadjuvant Chemoradiation
28. Circulating Tumor Cells With Markers of Epithelial-Mesenchymal Transition Are Associated With Distant Metastatic Failures in Lung Cancer Patients Treated With Definitive Chemoradiation
29. Circulating miR-155 Predicts for Acute Esophageal Toxicity in Patients With Non-Small Cell Lung Cancer Treated With Radiation Therapy
30. Serum TGF-β1 and VEGF Are Associated With Tumor Burden and Tumor Response on PET to (Chemo)radiation Therapy in Patients With Non-Small Cell Lung Cancer
31. Nomogram Score of Pathologic Complete Response to Neoadjuvant Chemoradiation Predicts for Survival Outcomes in Esophageal Cancer Patients Treated With Definitive Chemoradiation
32. Risk Factors Predicting Failure and Survival in Lung Cancer Patients Treated With Definitive Dose-Escalated Proton Radiation Therapy
33. Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer
34. Reirradiation With Proton Beam Therapy or Intensity Modulated Radiation Therapy for Non-small Cell Lung Cancer: An Institutional Experience
35. Patterns of Failure for Limited-Stage Small Cell Lung Cancer Following Definitive Radiation Therapy in the Modern Era
36. Impact of Chemotherapy Response and Radiation Dose on Overall Survival in Patients With Inoperable Non-small Cell Lung Cancer Treated With Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy
37. Prognostic Factors for Overall Survival in Stage IIIA/IIIB Non-small Cell Lung Cancer After Definitive (Chemo)radiation Therapy
38. Limited-Stage Small Cell Lung Cancer in the Contemporary Period: Impact of New Technologies on Outcomes
39. Improved Survival Outcomes in Non-small Cell Lung Cancer Patients With Incidental Concurrent Use of Beta-Blockers and Definitive Radiation Therapy
40. Heart and Lung Radiation and Overall Survival in Non-small Cell Lung Cancer Patients After Chemoradiation Therapy
41. Pretreatment Poor Pulmonary Function Is Prognostic of Poor Overall Survival in Patients With Stage III Non-small Cell Lung Cancer Treated With External Beam Radiation Therapy
42. IMRT Versus Passively Scattered Proton Therapy (PSPT) for Locally Advanced NSCLC -- Impact of Changing Techniques and Technologies Over the Course of a Randomized Trial
43. Patient Selection for Treatment Modality in Stage III Non-small Cell Lung Cancer: A Population-based Analysis
44. Treatment Modality and Other Prognostic Factors for Overall Survival in Stage III Non-small Cell Lung Cancer (NSCLC): A Population-based Analysis
45. Stereotactic Ablative Radiation Therapy for Multiple Primary Lung Cancer
46. Metformin Use is Associated With Improved Response to Neoadjuvant Chemoradiation in Esophageal Adenocarcinoma
47. Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy
48. Poor Glycemic Control During Radiochemotherapy Contributes to Reduced Local Control and Overall Survival in Patients With Non-small Cell Lung Cancer
49. Radiation Modality is a Strong Predictor for Postoperative Pulmonary and GI Complications After Trimodality Therapy for Esophageal Cancer
50. Experimental Evaluation of the Interplay Effect of Scanning Proton Beam for Small Moving Target in Heterogeneity Using a 4-dimensional Phantom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.